Published in Nat Commun on February 20, 2015
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. MBio (2016) 1.06
Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. Cell (2015) 1.00
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio (2015) 0.91
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology (2015) 0.91
Zika Virus: Immunity and Vaccine Development. Cell (2016) 0.89
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. J Immunol Res (2015) 0.85
Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. J Virol (2016) 0.84
Recent advances in understanding dengue. F1000Res (2016) 0.82
Plasmablasts During Acute Dengue Infection Represent a Small Subset of a Broader Virus-specific Memory B Cell Pool. EBioMedicine (2016) 0.82
The role of Fc receptors in HIV prevention and therapy. Immunol Rev (2015) 0.81
Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg (2016) 0.79
A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog (2017) 0.79
A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat Commun (2017) 0.79
The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol Mol Biol Rev (2017) 0.78
Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization. J Infect Dis (2015) 0.78
Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect (2017) 0.77
Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect Dis (2016) 0.77
Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine. PLoS One (2016) 0.77
Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight (2017) 0.76
Multiscale method for modeling binding phenomena involving large objects: application to kinesin motor domains motion along microtubules. Sci Rep (2016) 0.76
Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol Immunol (2015) 0.76
Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms. Clin Vaccine Immunol (2016) 0.76
Characterizing the Conformational Landscape of Flavivirus Fusion Peptides via Simulation and Experiment. Sci Rep (2016) 0.76
Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species. PLoS Curr (2016) 0.75
Modeling the Role of Epitope Arrangement on Antibody Binding Stoichiometry in Flaviviruses. Biophys J (2016) 0.75
Conformational changes in intact dengue virus reveal serotype-specific expansion. Nat Commun (2017) 0.75
Comparative Normal Mode Analysis of the Dynamics of DENV and ZIKV Capsids. Front Mol Biosci (2016) 0.75
Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine (2016) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone. mSphere (2017) 0.75
MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus. F1000Res (2016) 0.75
Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination. J Virol (2016) 0.75
Microsphere integrated microfluidic disk: synergy of two techniques for rapid and ultrasensitive dengue detection. Sci Rep (2015) 0.75
Dissecting the human serum antibody response to secondary dengue virus infections. PLoS Negl Trop Dis (2017) 0.75
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Front Microbiol (2017) 0.75
Potent Plasmablast-Derived Antibodies Elicited by the NIH Dengue Vaccine. J Virol (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
VMD: visual molecular dynamics. J Mol Graph (1996) 117.02
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics (2005) 34.83
Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res (1988) 32.89
The global distribution and burden of dengue. Nature (2013) 27.92
EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol (1999) 27.52
EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol (2006) 14.70
Dengue. Lancet (2007) 10.54
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Structure of the dengue virus envelope protein after membrane fusion. Nature (2004) 7.97
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics. Structure (2008) 5.97
Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res (2003) 4.90
Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J (2004) 4.05
The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol (2003) 3.83
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol (2005) 3.58
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Development of group- and serotype-specific one-step SYBR green I-based real-time reverse transcription-PCR assay for dengue virus. J Clin Microbiol (2003) 2.75
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology (2007) 2.40
Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 2.33
Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat Struct Mol Biol (2012) 2.27
Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology (2009) 2.26
Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol (2007) 2.15
Antigenic structure of flavivirus proteins. Adv Virus Res (2003) 2.15
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Early Dengue infection and outcome study (EDEN) - study design and preliminary findings. Ann Acad Med Singapore (2006) 2.12
Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell (2006) 2.08
The history and evolution of human dengue emergence. Adv Virus Res (2008) 2.05
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med (2012) 1.95
Averaging tens to hundreds of icosahedral particle images to resolve protein secondary structure elements using a Multi-Path Simulated Annealing optimization algorithm. J Struct Biol (2007) 1.90
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Structural changes in dengue virus when exposed to a temperature of 37°C. J Virol (2013) 1.60
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol (2011) 1.51
Critical issues in dengue vaccine development. Curr Opin Infect Dis (2011) 1.39
Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol (2007) 1.38
A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med (2014) 1.37
Neutralization of animal virus infectivity by antibody. Arch Virol (2007) 1.34
The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect (2006) 1.33
Dengue Vectors and their Spatial Distribution. Trop Med Health (2011) 1.19
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis (2013) 1.16
Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol (2012) 1.12
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol (2012) 1.12
Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J Virol (2013) 1.05
Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect (2010) 1.00
Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J Gen Virol (2011) 0.87